Ghisallo Capital Management LLC Makes New $8.25 Million Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Ghisallo Capital Management LLC purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 1,100,000 shares of the company’s stock, valued at approximately $8,250,000.

Other large investors also recently made changes to their positions in the company. Wedmont Private Capital lifted its stake in Recursion Pharmaceuticals by 11.8% during the first quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock valued at $172,000 after purchasing an additional 2,000 shares during the last quarter. Interchange Capital Partners LLC lifted its position in shares of Recursion Pharmaceuticals by 7.3% during the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after acquiring an additional 2,349 shares during the last quarter. Amalgamated Bank boosted its stake in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares in the last quarter. Benjamin F. Edwards & Company Inc. acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth $26,000. Finally, Victory Capital Management Inc. grew its holdings in shares of Recursion Pharmaceuticals by 13.5% in the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after acquiring an additional 2,598 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on RXRX shares. Needham & Company LLC reduced their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Jefferies Financial Group decreased their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Leerink Partners dropped their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Finally, KeyCorp decreased their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and an average price target of $9.40.

Insider Transactions at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total value of $83,792.04. Following the completion of the sale, the director now directly owns 7,167,110 shares in the company, valued at $52,463,245.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total value of $109,800.00. Following the transaction, the chief financial officer now owns 1,292,218 shares of the company’s stock, valued at $9,459,035.76. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $7.32, for a total transaction of $83,792.04. Following the sale, the director now directly owns 7,167,110 shares of the company’s stock, valued at $52,463,245.20. The disclosure for this sale can be found here. Insiders have sold a total of 231,682 shares of company stock worth $1,632,044 in the last 90 days. 15.75% of the stock is owned by insiders.

Recursion Pharmaceuticals Trading Down 6.4 %

NASDAQ RXRX opened at $6.17 on Wednesday. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 1-year low of $4.97 and a 1-year high of $15.74. The firm’s fifty day simple moving average is $6.95 and its 200-day simple moving average is $8.12. The company has a market capitalization of $1.73 billion, a PE ratio of -3.86 and a beta of 0.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The firm had revenue of $14.42 million for the quarter, compared to analysts’ expectations of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm’s revenue for the quarter was up 30.9% on a year-over-year basis. During the same period last year, the business earned ($0.38) earnings per share. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.